BioSpace News Archive

Following a partial hold on another lead candidate last year, Sanofi is reinvigorating its MS pipeline with a Phase II win for its investigational anti-CD40L antibody frexalimab.

The company’s blockbuster JAK inhibitor, alone or as a combination therapy, showed durable improvements in systemic lupus erythematosus disease activity at 48 weeks.

The company’s oral gut-targeting polymer, GLY-200, demonstrated promising safety and efficacy in patients with Type 2 diabetes, assessing the candidate as an adjunct treatment to diet and exercise.

Efforts are underway to fast-track approval for costly gene therapies and make them affordable to a wider patient group via reimbursement through Medicare and Medicaid.

The regulator will provide PepGen with a letter within 30 days explaining why a clinical hold was placed on the company’s Phase 1 study of patients with myotonic dystrophy Type 1.

Daré Bioscience, Inc., a leader in women’s health innovation, announced the publication of results of the patient-centered study designed to elucidate the commonly reported symptoms, including severity of symptoms, associated with female sexual arousal disorder.

Mineralys Therapeutics, Inc. today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will be giving a presentation at the Jefferies Healthcare Conference in New York at 9:30 a.m. ET on Friday, June 9, 2023.

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that it will implement the previously announced and stockholder approved 1-for-30 reverse split of its common stock.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301.

Pathalys Pharma, Inc. today announced that the first patient has been enrolled in the PATH (PTH Attenuation Trial in Hemodialysis) clinical program, consisting of two identical phase 3 trials, to assess upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in end-stage kidney disease (ESKD) patients on hemodialysis.